Nature Reviews Drug Discovery contents August 2015 Volume 14 Number 8 pp 511-587

If you are unable to see the message below, click here to view.

Advertisement
WHITE PAPER: The Role Of rasH2 In An Evolving Pharmaceutical Carcinogenicity Landscape  Changes to the ICH S1 guidelines have been proposed potentially transforming how pharmaceutical carcinogenicity evaluations are conducted.  Download To Learn More About: The background and limitations of existing protocols The potential impact of proposed changes to ICH S1 guidelines. How the rasH2 transgenic mouse meets the proposed guidelines Download Now
TABLE OF CONTENTS
August 2015 Volume 14 Number 8
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month Article series: Cancer immunotherapy  Featured article: ESKAPEing the labyrinth of antibacterial discovery Ruben Tommasi, Dean G. Brown, Grant K. Walkup, John I. Manchester & Alita A. Miller
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Genetics in association with the Wellcome Trust present: THE GENOMICS OF COMMON DISEASES 2015 September 2-5, 2015 | Cambridge, UK  REGISTER NOW!
Comment: Towards host-directed therapies for tuberculosis Alimuddin Zumla, Markus Maeurer and the Host-Directed Therapies Network p511 | doi:10.1038/nrd4696 The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
NCI-MATCH trial pushes cancer umbrella trial paradigm Asher Mullard p513 | doi:10.1038/nrd4694 An umbrella trial of 25 targeted treatments in all cancer types tackles treatment selection on the basis of genetic events rather than by tumour histology. PDF
Bacteriophage therapies re-enter clinical trials Katie Kingwell p515 | doi:10.1038/nrd4695 After decades of delays, biotechs hope that bacteria-attacking viruses could provide an alternative to traditional antibiotics. PDF
NEWS IN BRIEF FDA approvals for the first 6 months of 2015 Asher Mullard p517 | doi:10.1038/nrd4703 PDF
Vertex combo scores a broader cystic fibrosis approval Asher Mullard p517 | doi:10.1038/nrd4704 PDF
Calculating cancer drug value Asher Mullard p517 | doi:10.1038/nrd4705 PDF
BIOBUSINESS BRIEFS Market watch: Therapeutic area 'heat map' for emerging markets Ajay Gautam, Lily Li & Kumar Srinivasan p518 | doi:10.1038/nrd4656 PDF
BIOBUSINESS BRIEFS Patent watch: Drug patenting in India: looking back and looking forward Bhaven N. Sampat & Kenneth C. Shadlen p519 | doi:10.1038/nrd4681 PDF
AN AUDIENCE WITH Pierre Meulien p521 | doi:10.1038/nrd4698 Pierre Meulien, soon to be the new Executive Director of The Innovative Medicines Initiative, discusses his plans to move the European public-private partnership forward. PDF
FROM THE ANALYST'S COUCH Creating value with financially adaptive clinical trials Frank S. David, Sarah Bobulsky, Kraig Schulz & Nitin Patel p523 | doi:10.1038/nrd4682 This article discusses the opportunities and challenges in the application of financially adaptive clinical trials, which combine key aspects of adaptive trial design and financial analytics. PDF
RESEARCH HIGHLIGHTS Top Target validation: Genetic information adds supporting weight p525 | doi:10.1038/nrd4692 PDF Regenerative medicine: Inhibiting prostaglandin breakdown triggers tissue regeneration p526 | doi:10.1038/nrd4690 PDF Antifungal drugs: Designer non-toxic derivatives dodge resistance p526 | doi:10.1038/nrd4691 PDF Malaria: Hitting all stages of the parasite life cycle p527 | doi:10.1038/nrd4689 PDF Inflammatory diseases: Adding insult to allergy p528 | doi:10.1038/nrd4693 PDF IN BRIEF Diabetes: Osteoporosis drug promotes β-cell proliferation | Infectious disease: Fusion toxin protein inhibits CMV infection | Hypertension: BMP9 reverses PAH | Type 2 diabetes: ER stress modulator reverses diabetes PDF Drug Discovery JOBS of the week Multiple Openings Drug Discovery & Development at LACDR Universiteit Leiden Postdoctoral Research Fellow in Medicinal Chemistry for Cancer Drug Discovery University of Michigan Post-doctoral Fellow Massachusetts General Hospital & Harvard Medical School Postdoctoral Position in Functional Cancer Genomics Institute of Oncology Research Staff Scientist Baylor College of Medicine (BCM) More Science jobs from Drug Discovery EVENT Computational Advances in Drug Discovery 22.09.15 Lausanne, Switzerland More science events from
Advertisement
Simple, Rapid, Reproducible Collection of Plasma Offering significant advantages for use with LC-MS/MS instruments, Shimadzu’s Noviplex Cards allow for rapid collection of a volumetric sample of plasma (2.5 μL) from an unmeasured amount of whole blood (20 to 75 μL) within minutes. They can be used as a single step, solid-phase method for sample preparation and analyte extraction. Learn more.
PERSPECTIVES		Top
OPINION ESKAPEing the labyrinth of antibacterial discovery Ruben Tommasi, Dean G. Brown, Grant K. Walkup, John I. Manchester & Alita A. Miller p529 | doi:10.1038/nrd4572 Incentives are increasingly available for the development of new drugs to tackle antibiotic resistance, but major scientific challenges remain, such as achieving penetration into bacteria. Tommasi and colleagues describe AstraZeneca's experiences in antibacterial drug discovery over the past decade using both target-based and phenotypic screening approaches, and discuss the reasons for failure as well as strategies to improve cytoplasmic penetration. Abstract | Full Text | PDF
Advertisement
Ultra-Sensitive Biomarker Assay Service from PBL Assay Science  Dedicated assay team to execute & develop fit-for-purpose Single Molecule Array (SIMOA™) immunoassays: IL-6, IL-10, IL-17A, IL-23, IP-10, TNFa, TRAIL, 3-plexes, custom fg/ml sensitivities for analytes in serum, plasma, & other matrices Multiplexing capabilities  Let PBL help with your complex assay needs.
REVIEWS		Top
SLC transporters as therapeutic targets: emerging opportunities Lawrence Lin, Sook Wah Yee, Richard B. Kim & Kathleen M. Giacomini p543 | doi:10.1038/nrd4626 Solute carrier (SLC) transporters mediate a large number of physiological processes, and the dysfunction of individual transporters has been implicated in many Mendelian diseases. In this Review, Giacomini and colleagues summarize these roles and ways in which SLC transporters can be targeted by drugs, and highlight current and investigational drugs that modulate SLC transporters. Abstract | Full Text | PDF | Supplementary information
Article series: Cancer immunotherapy Combination cancer immunotherapy and new immunomodulatory targets Kathleen M. Mahoney, Paul D. Rennert & Gordon J. Freeman p561 | doi:10.1038/nrd4591 Anticancer immunotherapy through checkpoint blockade enables the patient to mount active antitumour responses and can dramatically improve survival. In this Review, Mahoney, Rennert and Freeman examine targets for next-generation immunomodulators and discuss how these may be integrated in rational combination therapies with existing and upcoming immune-targeted drugs. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Assessing drug safety in human tissues — what are the barriers? Anthony Holmes, Frank Bonner & David Jones p585 | doi:10.1038/nrd4662 Full Text | PDF | Supplementary information
Advertisement
Nature Collections TARGETING IL-17 IN INFLAMMATORY DISEASE  This Collection highlights the opportunities and potential benefits of interleukin-17-targeted therapies for chronic inflammatory diseases. Produced with support from  Eli Lilly and Company
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.